Aerovate Therapeutics Ownership
| AVTE Stock | USD 2.61 0.05 1.88% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Aerovate |
Aerovate Stock Ownership Analysis
About 100.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.94. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aerovate Therapeutics recorded a loss per share of 2.99. The entity had not issued any dividends in recent years. Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. Aerovate Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 25 people. For more info on Aerovate Therapeutics please contact Timothy MBA at 617 443 2400 or go to https://aerovatetx.com.Besides selling stocks to institutional investors, Aerovate Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Aerovate Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Aerovate Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Aerovate Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Aerovate Therapeutics Insider Trades History
Less than 1% of Aerovate Therapeutics are currently held by insiders. Unlike Aerovate Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Aerovate Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Aerovate Therapeutics' insider trades
Aerovate Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Aerovate Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aerovate Therapeutics backward and forwards among themselves. Aerovate Therapeutics' institutional investor refers to the entity that pools money to purchase Aerovate Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Octagon Capital Advisors Lp | 2024-06-30 | 465.4 K | Opaleye Management Inc | 2024-06-30 | 440 K | Gsa Capital Partners Llp | 2024-09-30 | 413.8 K | Ikarian Capital, Llc | 2024-06-30 | 368 K | State Street Corp | 2024-06-30 | 341.2 K | Geode Capital Management, Llc | 2024-06-30 | 317.2 K | Two Sigma Investments Llc | 2024-06-30 | 278.8 K | Verition Fund Managegment, Llc | 2024-06-30 | 249 K | Adar1 Capital Management Llc | 2024-06-30 | 246.9 K | Ra Capital Management, Llc | 2024-06-30 | 9.2 M | Sofinnova Ventures | 2024-06-30 | 3.8 M |
Aerovate Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aerovate Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aerovate Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aerovate Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aerovate Therapeutics Outstanding Bonds
Aerovate Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aerovate Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aerovate bonds can be classified according to their maturity, which is the date when Aerovate Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Aerovate Therapeutics Corporate Filings
| 18th of November 2024 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 31st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Aerovate Therapeutics is a strong investment it is important to analyze Aerovate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aerovate Therapeutics' future performance. For an informed investment choice regarding Aerovate Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aerovate Therapeutics. If investors know Aerovate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aerovate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.99) | Return On Assets (0.49) | Return On Equity (0.82) |
The market value of Aerovate Therapeutics is measured differently than its book value, which is the value of Aerovate that is recorded on the company's balance sheet. Investors also form their own opinion of Aerovate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aerovate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aerovate Therapeutics' market value can be influenced by many factors that don't directly affect Aerovate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aerovate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aerovate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aerovate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.